Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ovarian cancer vaccine - AVAX Technologies

Drug Profile

Ovarian cancer vaccine - AVAX Technologies

Alternative Names: DNP-Modified Ovarian Cancer Vaccine; O-Vax; OVax

Latest Information Update: 29 Jan 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVAX Technologies
  • Class Cancer vaccines; Conjugate vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Ovarian cancer

Most Recent Events

  • 26 Jan 2016 Efficacy data from a phase I/II trial in Ovarian cancer (Second-line therapy or greater) released by AVAX Technologies
  • 21 Sep 2015 Phase-I/II development in Ovarian cancer is ongoing in USA
  • 04 Aug 2015 AVAX completes enrolment in a phase I/II trial for Ovarian cancer in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top